| Inhibiting drivers of non-mutational drug tolerance is a salvage strategy for targeted melanoma therapy MP Smith, H Brunton, EJ Rowling, J Ferguson, I Arozarena, Z Miskolczi, ... Cancer cell 29 (3), 270-284, 2016 | 245 | 2016 |
| The immune microenvironment confers resistance to MAPK pathway inhibitors through macrophage-derived TNFα MP Smith, B Sanchez-Laorden, K O'Brien, H Brunton, J Ferguson, ... Cancer discovery 4 (10), 1214-1229, 2014 | 208 | 2014 |
| Endogenously induced DNA double strand breaks arise in heterochromatic DNA regions and require ataxia telangiectasia mutated and Artemis for their repair L Woodbine, H Brunton, AA Goodarzi, A Shibata, PA Jeggo Nucleic acids research 39 (16), 6986-6997, 2011 | 160 | 2011 |
| Targeting DNA damage response and replication stress in pancreatic cancer SB Dreyer, R Upstill-Goddard, V Paulus-Hock, C Paris, EM Lampraki, ... Gastroenterology 160 (1), 362-377. e13, 2021 | 105 | 2021 |
| HNF4A and GATA6 loss reveals therapeutically actionable subtypes in pancreatic cancer H Brunton, G Caligiuri, R Cunningham, R Upstill-Goddard, UM Bailey, ... Cell reports 31 (6), 2020 | 93 | 2020 |
| Visualisation of γH2AX foci caused by heavy ion particle traversal; distinction between core track versus non-track damage NI Nakajima, H Brunton, R Watanabe, A Shrikhande, R Hirayama, ... PloS one 8 (8), e70107, 2013 | 91 | 2013 |
| Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure MP Smith, EJ Rowling, Z Miskolczi, J Ferguson, L Spoerri, NK Haass, ... EMBO molecular medicine 9 (8), 1011-1029, 2017 | 71 | 2017 |
| Analysis of Human Syndromes with Disordered Chromatin Reveals the Impact of Heterochromatin on the Efficacy of ATM-Dependent G2/M Checkpoint Arrest H Brunton, AA Goodarzi, AT Noon, A Shrikhande, RS Hansen, PA Jeggo, ... Molecular and cellular biology 31 (19), 4022-4035, 2011 | 41 | 2011 |
| Formate induces a metabolic switch in nucleotide and energy metabolism K Oizel, J Tait-Mulder, J Fernandez-de-Cossio-Diaz, M Pietzke, H Brunton, ... Cell Death & Disease 11 (5), 310, 2020 | 40 | 2020 |
| FAK regulates IL-33 expression by controlling chromatin accessibility at c-Jun motifs BGC Griffith, R Upstill-Goddard, H Brunton, GR Grimes, AV Biankin, ... Scientific Reports 11 (1), 229, 2021 | 19 | 2021 |
| Using chromatin accessibility to delineate therapeutic subtypes in pancreatic cancer patient-derived cell lines H Brunton, IM Garner, UM Bailey, R Upstill-Goddard, PJ Bailey STAR protocols 1 (2), 100079, 2020 | 6 | 2020 |
| PDAC Subtypes/Stratification H Brunton, G Caligiuri, GJ Inman, P Bailey Translational Pancreatic Cancer Research: From Understanding of Mechanisms …, 2020 | 2 | 2020 |
| AB001. S001. Defining DDR deficiency and replication stress in pancreatic cancer SB Dreyer, V Paulus-Hock, E Lampraki, R Upstill-Goddard, G Caligiuri, ... Annals of Pancreatic Cancer 1 (4), 2018 | | 2018 |
| Proffered Paper: Utilising non-mutational drug-tolerance prolongs and improves targeted melanoma therapy MP Smith, H Brunton, EJ Rowling, MR Girotti, R Marais, R Dummer, ... European Journal of Cancer 1 (61), S2-S3, 2016 | | 2016 |
| Investigating the role of higher order chromatin structure and DNA damage complexity on ATM signalling and G2/M checkpoint arrest H Brunton University of Sussex, 2011 | | 2011 |
| The regulation of the epigenetics (chromatin structures) in the target cells enhances the efficacy of heavy ion irradiation N Izumi-Nakajima, H Yajima, H Hirakawa, A Fujimori, R Okayasu, ... | | 2011 |
| MITF and the response to MAP-kinase pathway targeting therapy in melanoma M Smith, H Brunton, S Rana, J Ferguson, I Arozarena, S Speldewinde, ... | | |
